Evotec SE
EVT.DE
Deutsche Börse5.03
EUR
+0.01
- -
ISIN
DE0005664809
CUSIP
D1646D105
Return %
Stock
S&P500
1Y
-29.55
26.57
3Y
-76.44
76.60
5Y
-85.98
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christian Wojczewski
- Full Time Employees
- 4,766
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Essener Bogen 7 Hamburg Germany 22419
- IPO Date
- Nov 12, 1999
- Website
- evotec.com
- Similar Companies
- Business
- Evotec SE operates as a global biotechnology company specializing in drug discovery and development solutions for the pharmaceutical and biotechnology industries worldwide. Its main products and services include drug discovery platforms and preclinical development in therapeutic areas such as neuroscience, diabetes, pain and inflammation, oncology, infectious diseases, respiratory and fibrotic diseases, cardiometabolic diseases, rare diseases, and women and animal health. Key segments include Shared R&D, which focuses on drug discovery and preclinical development leveraging automation, next-generation platforms, and AI to accelerate customer projects, and Just – Evotec Biologics, which designs, develops, and manufactures biologics through advanced continuous manufacturing technologies. Evotec provides integrated molecular design, upstream and downstream development, analytical and formulation development, and First-In-Human to commercial GMP biologics manufacturing services. The company serves pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capital worldwide, with operational presence in Germany, the United States, France, the United Kingdom, Switzerland, and other international locations. Founded in 1993 and headquartered in Hamburg, Germany, Evotec transitioned from Evotec AG to Evotec SE in 2019. Recent major changes include a transformational strategic agreement with Sandoz, announced in 2025, under which Sandoz will acquire 100% of Evotec's Just – Evotec Biologics EU manufacturing site in Toulouse along with an indefinite license to Evotec's proprietary continuous manufacturing platform. This transaction, valued at over $650 million including upfront payments, license fees, development revenues, and future royalties on a portfolio of biosimilars, marks a pivot to an asset-lighter business model for Evotec focused on technology provision and scalable biologics manufacturing services. This deal significantly enhances Evotec’s revenue mix and capital efficiency. Additionally, Evotec unveiled a new strategic focus in 2025 to concentrate on its core strengths in drug discovery and science leadership, emphasizing technology platforms and AI-driven innovation. New partnerships include multi-year research collaborations with Pfizer centered on metabolic and infectious diseases and a technology development partnership with Novo Nordisk to support next-generation cell therapies. These strategic moves underpin Evotec’s goal of sustainable, profitable growth while simplifying its business model and streamlining its asset portfolio by approximately 30 percent. Evotec’s integrated R&D value chain, proprietary technology platforms, and partnerships position it as a pioneering service partner in drug discovery and biologics manufacturing, delivering speed, efficiency, and quality solutions to accelerate development timelines and improve therapeutic outcomes. The company remains focused on advancing cutting-edge science, expanding its global footprint, and scaling its offerings to meet the evolving needs of the pharmaceutical and biotechnology sectors.